ABSTRACT Lipoproteins are a heterogeneous population of macromolecular aggregates of lipids and proteins that are responsible for the transport of lipids through the vascular and extravascular fluids from their site of synthesis or absorption to peripheral tissues. Lipoproteins are involved in other biological processes as well, including coagulation and tissue repair, and serve as carriers of a number of hydrophobic compounds within the systemic circulation. It has been well documented that disease states (eg, AIDS, diabetes, cancer) significantly influence circulating lipoprotein content and composition. Therefore, it appears possible that changes in the lipoprotein profile would affect not only the ability of a compound to associate with lipoproteins but also the distribution of the compound within the lipoprotein subclasses. Such an effect could alter the pharmacokinetics and pharmacological action of the drug. This paper reviews the factors that i nfluence the interaction of one model hydrophobic compound, cyclosporine A, with lipoproteins and the implications of altered plasma lipoprotein concentrations on the pharmacological behavior of this compound.
INTRODUCTION
Lipoproteins are a heterogeneous population of macromolecular aggregates of lipids and proteins that are responsible for the transport of lipids through the vascular and extravascular fluids from their site of synthesis or absorption to peripheral tissues 1, 2 . Lipids, which include Triglycerides (TG) and cholesteryl esters (CE), are delivered from the liver and intestine to other tissues for storage or catabolism in the production of energy. Lipoproteins are involved in other biological processes as well, including coagulation and tissue repair, and serve as carriers of a number of hydrophobic compounds within the systemic circulation 1, 2 .
It has been well documented that disease states significantly influence circulating lipoprotein content and composition. Therefore, it appears possible that changes in the lipoprotein profile would affect not only the ability of a compound to associate with lipoproteins but also the distribution of the compound within the lipoprotein subclasses. Such an effect could alter the pharmacokinetics and pharmacological action of the drug. This paper reviews the factors that influence the interaction of one model hydrophobic compound, cyclosporine A (CSA), with lipoproteins and the implications of altered plasma lipoprotein concentrations on the pharmacological behavior of this compound.
LIPOPROTEIN STRUCTURE Lipoproteins are spherical
particles consisting of a nonpolar lipid core (TG and CE) surrounded by a surface monolayer of amphipathic lipids (phospholipids and unesterified cholesterol) and specific proteins called apolipoproteins (1,2. A number of different phospholipids are incorporated into the coat of the lipoprotein, the more common of which are phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, and sphingomyelin. The most abundant of these phospholipids is phosphatidylcholine, which is also utilized as a substrate in the esterification of cholesterol to cholesteryl ester by the enzyme lecithin:cholesterol acyltransferase. Since lipids, in general, have lower buoyant densities than proteins, lipoproteins with a larger amount of lipid relative to protein will have a lower density than lipoproteins with a smaller lipid-to-protein ratio 1, 2 . Traditionally, plasma lipoproteins are classified and separated according to their density and are divided into 5 main categories: chylomicrons, very low density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) 1, 2 . Chylomicrons, with a diameter of approximately 100 to 1000 nm, are the largest of the lipoproteins and are found in greatest abundance after a meal. Chylomicrons are synthesized by the intestine and are core-rich in TG derived from dietary fat. VLDL are the next largest lipoproteins (diameter = 30-80 nm) and are also rich in TG. VLDL are synthesized mainly by the liver but may also be synthesized to a lesser degree by the intestine. 3, 4 . It interacts with the intracellular protein cyclophilin, which inhibits the calcium-dependent translocation of nuclear transcription factors, which are necessary for interleukin-2 gene transcription. Since interleukin-2 is required for the proliferation of T lymphocytes, CSA is capable of diminishing the immune response 3 , 4 . However, despite its effectiveness as an immunosuppressant, the use of CSA is limited by renal toxicity, which is characterized by a rise in serum creatinine and a decrease in the glomerular filtration rate 3 .
A number of laboratories, including ours, have shown CSA to associate with lipoproteins upon incubation in human plasma 2 , 4 -10 , resulting in a modification of its pharmacological activity. De Kippel et al 6 have reported decreases in CSA activity in patients who have elevated plasma triglyceride levels, while de Groen et al 7 have observed increases in cyclosporine toxicity in those with hypolipidemia. Lemaire et al have observed enhanced antiproliferative effects of CSA when the drug was associated with LDL; these effects were not evident when the drug was associated with either VLDL or HDL 9, 10 . Gardier et al observed that heart transplant patients with high total plasma cholesterol levels demonstrated increased CSA association with plasma LDL and increased CSA-induced renal toxicity compared with normolipidemic controls 8 . In addition, Arnadottir et al observed elevations in CSA-induced renal toxicity in kidney transplant patients who exhibited increases in plasma cholesterol concentration 11 . Taken together, these studies provide substantial evidence suggesting that plasma lipoprotein lipid levels have a major impact on the efficacy and toxicity of CSA. 14 . CETP expression between mammalian species is variable, with undetectable levels in rats and mice and moderate levels in humans and rabbits 15 . The majority of CETP in humans is synthesized in the liver, with lower levels produced in the adipose tissue, kidney, heart, and spleen 16, 17 .
FACTORS THAT INFLUENCE CSA INTERACTIONS WITH PLASMA LIPOPROTEINS
CETP facilitates the transfer of CE from HDL to apoBcontaining lipoproteins (VLDL and LDL) with a reciprocal transfer of TG 16, [18] [19] [20] . CETP, along with PLTP, plays an important role in the metabolism and remodeling of plasma lipoproteins 21, 22 . CETP may also play a role in certain disease processes such as atherosclerosis by redistributing cholesterol from the antiatherogenic HDL particles to the proatherogenic LDL particles. Conversely, CETP is also implicated in the process of reverse cholesterol transport, which removes cholesterol from peripheral tissues and is viewed as antiatherogenic. The exact role of CETP in the development of atherosclerosis remains uncertain and is the subject of various studies 17 . Since the human body may recognize hydrophobic compounds as lipidlike particles, we have hypothesized that an increase in CETP concentration may facilitate the movement of drugs such as CSA among different lipoprotein classes. Evidence to support this hypothesis is presented in the following paragraphs. When CSA was incubated in human plasma with or without additional supplementation of CETP, for 60 minutes at 37ºC, increases in CETP concentration resulted in an increased percentage of CSA recovered in the HDL/lipoprotein-deficient plasma (LPDP) fraction (Table 1) 
.
Additional experiments-designed to directly measure the potential role of CETP to facilitate CSA transferdemonstrated that CETP -mediated percentage transfer of CE among HDL and LDL particles in human plasma was significantly different from that of CSA (Table 2) 23 . The differences in the percentage transfer of CE versus CSA may be attributed to an ability of CETP to transfer lipids and drugs separately. Furthermore, differences could be attributed to the ability of HDL and LDL particles to accumulate a higher amount of CE than CSA.
In addition, when CETP-mediated transfer of CE between HDL and LDL was inhibited by TP2 (a monoclonal antibody directed against CETP), only the transfer of CSA from LDL to HDL was significantly decreased ( Table 2) 23 . These results suggest that the transfer of CSA from LDL to HDL is partially facilitated by CETP, while the transfer of CSA from HDL to LDL is facilitated not by CETP but by other plasma factors and/or by spontaneous transfer. This notion is supported by the work of Hughes et al, who hypothesize that the plasma distribution of CSA is determined by factors other than simple diffusion between lipoprotein particles 24 . These findings suggest that the distribution/redistribution of CSA among plasma lipoproteins facilitated by CETP may serve as a possible mechanism for determining the ultimate fate of these compounds.
INFLUENCE OF LIPOPROTEIN CONCENTRATION AND COMPOSITION A second feature of dyslipidemic plasma
is the increase and/or decrease in plasma lipoprotein cholesterol and triglyceride concentrations. Since CSA associates with plasma lipoproteins following their administration, our laboratory has hypothesized that changes in lipoprotein concentration and composition would alter the lipoprotein distribution of CSA.
Our laboratory reported that broad plasma dyslipidemias ( Table 3 ) and specific increases in LDL and VLDL lipid levels ( Table 4 ) resulted in an increasing amount of CSA recovered in these fractions and a significant decrease in the amount of CSA recovered in the HDL fraction (Tables 3 and 4) 5 . Furthermore, the amount of drug recovered in the nonlipoprotein fraction remained unchanged. These findings suggest that CSA lipoprotein distribution may be partially regulated by plasma lipoprotein cholesterol and to a lesser extent triglyceride concentrations. It further suggests that the redistribution of drug from one lipoprotein class (HDL) to another (LDL or VLDL) could be influenced by different disease states and adjunct therapies such as intralipid infusion, in which lipoprotein plasma concentrations and composition are altered 25 .
In addition, we observed that increasing the TG:total cholesterol (TC) ratio within VLDL and HDL resulted in more CSA recovered in the VLDL fraction but less CSA recovered in the HDL fraction 5 . However, increases in the HDL TG:TC ratio increased the amount of drug recovered in the HDL fraction 5 . These findings suggest that not only lipid mass (TC and TG) and lipoprotein composition but also the type of lipoprotein in which these changes occur is another possible factor in determining the lipoprotein CSA associates with. Since transplantation patients exhibit lipid disturbances, including decreased cholesterol levels and/or elevated triglyceride levels, these results may provide an explanation for the unpredictable and inconsistent pharmacokinetics and pharmacodynamics of CSA following administration.
CELLULAR UPTAKE AND TOXICITY STUDIES It has
been suggested that cellular uptake of CSA may be mediated through hepatic HDL 24 and LDL receptors 26 , although others have reported that lipoproteins may not serve as vehicles for cellular uptake of CSA into hepaticderived cells 27 . It has been suggested that CSA availability to tissue, and hence its pharmacological or toxic effects, may depend on the lipoprotein with which CSA is associated 9 . An enhanced antiproliferative effect of CSA has been observed when the drug was associated with LDL but not with VLDL or HDL 10 .
Recently, we have shown that the uptake and toxicity of CSA within LLC-PK1 pig kidney cells were effectively reduced with elevated LDL concentrations (Figure 1 ) but showed a significant increase when incubated with elevated concentrations of apoA-I (data not shown) 28 . Increasing VLDL and HDL concentrations slightly reduced CSA toxicity and uptake but showed little effect with increased incubation time. Triglyceride and cholesterol, the respective major components of VLDL and LDL, did not alter CSA uptake or toxicity under the conditions tested. LDL and apoA -I are identified as the major effectors of CSA toxicity and uptake in LLC-PK1 cells. The data presented here clearly demonstrate a relationship between CSA-induced toxicity and the nature of the associated lipoprotein 28 . Taken together, these findings suggest that CSA uptake may be mediated through receptors such as the LDL receptor or those involved in protein reabsorption. Lipoproteins are i nvolved in other biological processes as well, including coagulation and tissue repair, and serve as carriers of a number of hydrophobic compounds within the systemic circulation. It has been well documented that disease states (eg, AIDS, diabetes, cancer) significantly influence circulating lipoprotein content and composition. Therefore, it appears possible that changes in the lipoprotein profile would affect not only the ability of a compound to associate with lipoproteins but also the distribution of the compound within the lipoprotein subclasses. Such an effect could alter the pharmacokinetics and pharmacological action of the drug. This paper reviewed the factors that infl uence the interaction of CSA with lipoproteins and the implications of altered plasma lipoprotein concentrations on the renal cytotoxicity of this compound.
